Related by context. All words. (Click for frequent words.) 60 Relivar 59 punctal plug 59 cannabinor 58 ruxolitinib 58 Tarsa oral calcitonin 58 INT# [002] 58 epinastine 58 ularitide 57 liposomal formulation 57 favorable pharmacokinetic profile 57 HuMax EGFr 57 DACH platinum 57 PROMACTA ® 56 CCX# 56 TRX1 56 brivaracetam 56 UPLYSO 56 Ventavis ® 56 vidofludimus 56 IIa trial 56 O PPDS 56 Technosphere Insulin 56 fosbretabulin 56 QT QTc 56 Hedgehog antagonist 55 rxRNA 55 punctal plug delivery 55 JAK2 inhibitor 55 OncoVEX 55 isoform selective 55 novel histone deacetylase 55 EDEMA3 55 Ophena 55 ARIKACE ™ 55 lumiliximab 55 JAK inhibitors 55 GAP #B# 55 HGS ETR2 55 EVIZON ™ 55 dose proportionality 55 TransVax tm 54 Trofex 54 PDE4 inhibitor 54 Phase 1a clinical 54 sitaxsentan 54 Panzem R NCD 54 AERx iDMS 54 preclinically 54 zotarolimus 54 AeroLEF TM 54 CIMZIA ™ 54 Phase IIa trials 54 Retisert 54 HYLENEX recombinant 54 PSMA ADC 54 CRMD# 54 Spiegelmer ® 54 Anticalin R 54 HQK 54 successfully commercialize Iluvien 54 enoximone 54 TriGrid ™ 53 clonidine hydrochloride 53 paraprotein 53 selective modulator 53 GAMMAGARD 53 ADAGIO study 53 BrachySil TM 53 oral ridaforolimus 53 durable remissions 53 ATL# [001] 53 QuadraSphere 53 rindopepimut 53 EGS# 53 Optiquel ™ 53 GLP toxicology studies 53 MVA BN 53 EOquin 53 Virulizin ® 53 pharmacokinetic equivalence 53 PDE4 inhibitors 53 Plicera 53 BLA filing 53 INTEGRILIN 53 HGS# 53 SLx 53 RSD# 53 Alequel ™ 53 MERLIN TIMI 53 pharmacokinetic PK profile 53 MEND CABG II 53 refractory CLL 53 viral kinetics 53 eTag assays 53 MET inhibitor 53 Orally administered 53 pharmacodynamic PD 53 DCCR 53 intranasal insulin 53 Aerosurf 53 systemic RNAi 52 REMUNE R 52 HCD# [002] 52 Phase III confirmatory 52 antiangiogenic activity 52 CytoFabTM 52 UVIDEM 52 liposome formulation 52 NEVO ™ 52 VEGF inhibitor 52 CIP TRAMADOL ER 52 tubulin inhibitor 52 Spheramine 52 oral treprostinil 52 QTinno 52 vascular disrupting agents 52 Thorough QT 52 orBec 52 analgesic efficacy 52 MoxDuo 52 elagolix 52 XmAb# 52 photoprotective drug 52 Trp p8 52 ASONEP 52 ENMD # 52 Lixivaptan 52 NasalFent 52 potency selectivity 52 preclinical efficacy 52 Potelligent Technology 51 antiangiogenic therapy 51 nanopharmaceutical 51 samalizumab 51 CRLX# 51 Solorel TM 51 Resolute DES 51 mg/m2 cohort 51 Aurora kinase inhibitor 51 PROCHYMAL 51 tecarfarin 51 generation FBPase inhibitor 51 Squalamine 51 Afatinib 51 Q#IR 51 XOPENEX Inhalation Solution 51 GnRH antagonist 51 SERCA2a 51 BNC# 51 Sensipar 51 novel oral anticoagulant 51 ALN HTT 51 TOLAMBA 51 LB# [003] 51 Phase 1b trial 51 ACZ# 51 bortezomib Velcade 51 targeting PCSK9 51 cMET 51 IPL# 51 A3 adenosine receptor 51 indibulin 51 tipranavir r 51 xanthine oxidase inhibitor 51 BCR ABL inhibitors 51 Aerovant 51 injectable formulations 51 bupropion HCl 51 TAXUS TM 51 hA# 51 FBPase 51 cystinosis patients 51 ABSORB trial 51 Targretin capsules 51 OvaRex R 51 efficacy endpoint 50 Glypromate 50 NY ESO 50 Removab 50 MCOT TM 50 Cimzia TM 50 histone deacetylase HDAC 50 Proellex TM 50 novel VDA molecule 50 anti angiogenic agent 50 clinically meaningful 50 QTinno TM 50 NeuVax 50 Endeavor DES 50 Zemplar Capsules 50 phase IIa clinical 50 IgG1 antibodies 50 EPC# 50 GRN# 50 canakinumab 50 alicaforsen enema 50 MAXY alpha 50 imatinib therapy 50 PTHrP 50 CobaCyte 50 Xerecept 50 gallium containing 50 MYLOTARG 50 Genz # 50 Preclinical studies 50 AMPK activators 50 PI3 kinase inhibitors 50 HERmark assay 50 pediatric acute lymphoblastic 50 PLAVIX ® 50 bucindolol 50 TroVax ® 50 Neuromodulation System 50 small molecule tyrosine 50 cediranib 50 carcinoembryonic antigen CEA 50 investigational antiplatelet 50 clevidipine 50 Tracleer R 50 doxorubicin docetaxel 50 mTOR inhibition 50 CCR9 antagonist 50 ganaxolone 50 glucagon receptor 49 Zyclara 49 Hemopurifier ® 49 tropism testing 49 MetMAb 49 drug eluting stent DES 49 elvucitabine 49 Tekmira SNALP technology 49 oxaliplatin Eloxatin 49 immatics 49 radiolabeled 49 Zevalin consolidation 49 symptomatic paroxysmal AF 49 sargramostim 49 RH1 49 Cand5 49 JAK#/JAK# inhibitor CYT# 49 IIa trials 49 non metastatic osteosarcoma 49 DepoVax ™ 49 synthase TS 49 Isolagen Process 49 BEXXAR 49 intact parathyroid hormone 49 HCV protease inhibitors 49 omacetaxine mepesuccinate 49 OvaRex MAb 49 ACTEMRA TM 49 deforolimus 49 Multiple Ascending Dose 49 peak plasma concentrations 49 Pharmacokinetic parameters 49 RLY# 49 levodopa carbidopa 49 TLR agonists 49 BeneFIX 49 vivo potency 49 Phase #b/#a 49 ® natalizumab 49 PSN# [001] 49 LHRH antagonists 49 Eligen R B# 49 SNT MC# 49 lenalidomide dexamethasone 49 Maximum Tolerated Dose 49 PEGPH# 49 NEUGENE antisense 49 RONDEL 49 OvaRex 49 initiate Phase 1b 49 TKM PLK1 49 antiviral potency 49 2 methoxyestradiol #ME# 49 CAPHOSOL 49 bioequivalency 49 FOLFOX regimen 49 OrCel 49 faropenem 49 bevasiranib 49 triphendiol 49 neuroprotective properties 49 Protelos 49 Cinquil 49 ESTRASORB 49 dasatinib Sprycel 49 TNF alpha inhibitor 49 everolimus eluting stents 49 clinical pharmacology studies 49 TTR gene 48 SURFAXIN r 48 inhaled AAT 48 convenient dosing regimens 48 antiandrogen 48 dose escalation Phase 48 R roscovitine 48 BRAF inhibitors 48 chimeric monoclonal antibody 48 Tyrima 48 Aplidin 48 opioid bowel dysfunction 48 carcinoembryonic antigen 48 Zavesca r 48 adenosine injection 48 Src inhibitors 48 darunavir r 48 ANAVEX #-# [001] 48 HuCAL antibodies 48 BenzEFoam 48 Pyridorin 48 Valortim ® 48 GENASIS trial 48 HEK# cells 48 adjuvant AS# 48 AIR# [001] 48 IL #E 48 Zavesca ® 48 B. Lynne Parshall 48 ADVEXIN therapy 48 microdose 48 CCR5 antagonist 48 peptidomimetic 48 gonadotrophin releasing hormone GnRH 48 oblimersen 48 CHAMPION PLATFORM 48 Firazyr 48 Fc fusion protein 48 QVAR 48 Dextofisopam 48 TriRima 48 InterfeRx 48 ® pioglitazone HCl 48 initiate Phase IIa 48 XERECEPT R 48 AnorMED expectation 48 VLP vaccines 48 PyratineXR 48 ulimorelin 48 IL 1ß 48 naltrexone SR 48 IgG1 antibody 47 CINOD 47 cortical stimulation 47 prGCD 47 effector function 47 biomarker assay 47 pharmacokinetic pharmacodynamic 47 selective agonists 47 Flutiform TM 47 VaxImmune 47 XR NTX 47 CB2 selective 47 Anticalin 47 immunomodulation 47 genotypic resistance 47 Hedgehog inhibitor 47 target lesion revascularizations 47 outlicensing 47 Biomerk Tumorgrafts 47 statistically significant efficacy 47 pharmacodynamics PD 47 HuCAL 47 confirmatory clinical 47 #mg BID [002] 47 Harry Palmin President 47 TLR antagonists 47 K DOQI guidelines 47 favorable tolerability 47 trastuzumab emtansine T DM1 47 antibody humanization 47 somatostatin receptor 47 randomized Phase 2b 47 REMINYL ® 47 opioid analgesia 47 Urocidin 47 siRNA mediated 47 Pentraxin 2 47 VITAL Trial 47 antihypertensive therapies 47 favorable pharmacokinetic 47 selective agonist 47 VIBEX MTX 47 Dose escalation 47 DAPT 47 Hydrochloride tablets 47 schizophrenia CIAS 47 OnDose 47 Arsenic trioxide 47 interferon beta therapy 47 Pharmacokinetic analyzes 47 rhFVIIa 46 relapsed SCLC 46 pharmacological chaperone 46 Vascugel R 46 PEP# [003] 46 folate receptor 46 CXCR7 46 CCR2 46 peptide conjugated 46 K ras mutations 46 FAMPYRA 46 Pitavastatin 46 vascular disrupting agent 46 Evoltra 46 pharmacokinetics PK 46 DP b# 46 Toraymyxin TM 46 NurOwn ™ 46 BioMatrix TM 46 recurrent glioblastoma 46 Cipralex ® 46 ALV# 46 CanAg 46 ischemic tissues 46 plasma renin activity 46 prostatic tissue 46 Option IVC Filter 46 MorphoSys proprietary 46 Angiox ® 46 somatostatin receptors 46 CTCE 46 mTOR inhibitors 46 hematological tumors 46 2A/Furin technology 46 MIST II 46 serotonin synthesis 46 mutated KRAS 46 TRIST study 46 XL# SAR# 46 Solasia 46 demonstrated clinically meaningful 46 targets Galectin receptors 46 immune modulating 46 Kevetrin ™ 46 antiangiogenic agent 46 Vidofludimus 46 anti leukemic 46 Rubicon Filter 45 PROactive study 45 Tarvacin TM 45 rituximab monotherapy 45 JAK2 inhibitors 45 MET amplification 45 delipidation 45 PROSTVAC ® 45 Trofile assay 45 novel nucleoside analog 45 thymidylate synthase TS 45 inhibits VEGF 45 Tesmilifene 45 commented Alexis Borisy 45 murine mouse 45 Hsp# inhibition 45 citicoline 45 human microdosing 45 OVA TM 45 mucosal healing 45 Postoperatively 45 Myoblast Program 45 T#I mutation 45 debulking surgery 45 antiapoptotic 45 drug elution 45 MAGE A3 45 Platinum Chromium 45 HYC# 45 antidepressant efficacy 45 IgM isotype 45 OMAPRO 45 anti fibrotic 45 Eligen R Technology 45 GPNMB 45 taxane derivative 45 multicenter clinical trials 45 imexon 45 Aeolus Pharmaceuticals Announces 45 hematological parameters 45 Vectibix panitumumab 45 LHRH receptors 45 Akt inhibitor 45 IVTA 45 PREVU 45 oxidative stress inducer 45 Pegintron 45 inflatable penile prosthesis 45 siRNAs targeting 45 Pharmacokinetic studies 45 Lyn kinase 45 cytokine refractory 45 fibrotic disease 45 anti arrhythmic 45 recombinant albumin 45 TAXUS Express Stent 45 MICARDIS ® 45 Voraxaze ™ 45 radiographic outcomes 44 SOD1 gene 44 NeuroSolutions 44 initiate Phase 2b 44 rechallenge 44 GDIR 44 antisense inhibition 44 Gleevec resistant 44 NTCD 44 5 HT2C receptor 44 nucleoside naive patients 44 therapeutically relevant 44 MUC1 44 Toric IOL 44 mediated inhibition 44 activated lymphocytes 44 retaspimycin 44 TLE3 44 TGR5 44 atherogenic lipids 44 intranasal ketamine 44 chemosensitivity 44 EB# ® 44 Discovery Labs KL4 44 potently inhibits 44 PathFinderTG 44 mTOR mammalian target 44 stavudine d4T 44 MYTHOS trial 44 HIV coinfected 44 Nav#.# 44 homocysteine assay 44 subcutaneous immunoglobulin 44 cardioprotective effects 44 docetaxel emulsion 44 antiviral efficacy 44 surgically resectable 44 patients evaluable 43 immunogen 43 taxane therapy 43 intestinal mucosal 43 ZFP 43 TrialMaster 43 haematological cancers 43 OGG1 43 mesothelin 43 dose dependently 43 glioblastoma tumors 43 botanically derived 43 MGMT methylation 43 Combination therapy 43 potent stimulator 43 labetuzumab 43 Tumor shrinkage 43 PI3K/mTOR 43 genotoxicity 43 oral prednisolone 43 relapsed ALL 43 RenalGuard System TM 43 selectively binds 43 TNFR1 43 evaluable patients 43 selective kinase inhibitors 43 JAK#/JAK# 43 Phase #/#a clinical 43 liver histology 43 NKX#.# 43 maximally tolerated 43 Angioblast 43 lesional 43 aurora kinase inhibitor 43 Therapeutic Diagnostics 42 periprocedural MI 42 norepinephrine reuptake inhibition 42 CTx 42 IFN alpha 2b 42 Mesothelin 42 Arisaph 42 ION Stent 42 mCRPC 42 selectively inhibited 42 hESC derived cells 42 antigenic peptides 42 V#F 42 predialysis 42 allergic airway inflammation 42 Subgroup analysis 42 resVida ® 42 SNALP formulations 42 estrogen receptor beta 42 Cre recombinase 42 fludarabine cyclophosphamide 42 Loretta M. Itri 42 differ materially fromthose 42 Carotid endarterectomy 42 STX# 42 epithelial cells lining 42 SIMPADICO 42 CD# antigen 42 proprietary phage display 42 Randomized clinical trials 42 SIRT1 enzyme 42 HalcyGen 42 plasminogen activators 42 TAKSTA 42 urodynamic 42 Sensitivity analyzes 42 EGFR protein 42 galectins 42 Provent Therapy 42 phage display technology 42 MetAP2 42 ErbB 42 orimplied 42 trans retinoic acid ATRA 42 TAXUS stents 41 Xenopus oocytes 41 reproducibly 41 MAGE A3 protein 41 recombinant antithrombin product 41 aEURoeThis 41 kinase inhibition 41 Microdosing 41 ImmuneY2 41 regarding allosteric modulators 41 Perkinamine 41 human monoclonal antibody 41 Activated Checkpoint Therapy 41 adenosine deaminase 41 mutated K ras 41 immunostimulatory effects 41 Freund adjuvant 41 AGTR1 41 pituitary hormone 41 NNRTI resistance 41 ERb 41 SCENESSE 41 ionophore 41 aza anthracenedione molecular 41 prognostic indicators 40 lung metastases 40 differmaterially 40 PRESEPT study 40 Phospha E 40 PRESEPT 40 Modrenal 40 VIDAZA ® 40 Fc receptor 40 Ultrafast Insulin 40 Mycophenolate mofetil 40 cancer immunotherapeutics 40 Thorough QT TQT 40 Antioxidant supplements 40 Pharmacokinetic analysis 40 HER-2/neu 40 biosimilar insulin 40 metastatic melanomas 40 patient subpopulations 40 unconfirmed cytogenetic response 40 QSAR models 40 lutetium plus 40 radiosensitivity 40 refractory colorectal cancer 40 eClinical suite 40 nanomolar potency 39 Adverse events 39 DLL4 39 cardioprotection 39 attain statistical significance 39 DNA demethylation 39 SpHb monitoring 39 p# Shc 39 differ materiallyfrom 39 todiffer materially 39 pressure natriuresis 39 melatonin receptor 39 coexpression 39 preterm lamb 39 GPR# [001] 39 Mr. Owusu Akyaw 39 angiogenic 39 d Neal Auction 39 FSH receptor 39 intravenous CK # 39 glucocerebrosidase GCD 39 EGFR mutation status 39 Doral ® quazepam 39 lipid nanoparticles LNPs 39 Transgenic mice 39 onset AF 39 CD# receptor 38 Fracture Intervention Trial 38 CLL8 38 c myc gene 38 LV dysfunction 38 pharmacophore 38 chromosome #p# [002] 38 serum lipid 38 hCG beta 38 Zelnorm Zelmac 38 alpha7 NNR 38 AIM HIGH 38 Oncotype DX Recurrence Score 38 OPAXIO pixantrone 38 AAV2 38 Virologic failure 38 Randomized trials 38 Diamyd r vaccine 38 constitutively 38 Dr. Bahcall 38 NNRTI resistant virus 38 commercially producible 38 Agennix AG 38 -Amos Harel Haaretz Correspondent 38 phosphorylase 38 sequence tags ESTs 37 MLL AF9 37 PSMA protein 37 fructosamine 37 lamivudine resistant 37 multivariate regression 37 liver fibrosis cirrhosis 37 Importantly 37 peritoneal carcinomatosis 37 Cheniere Energy Partners 37 Phase Ib IIa clinical 37 HER2/neu protein 37 ICSs 37 aptamer therapeutics 37 unimaginable savagery thousands 37 factor receptor EGFR 37 lutetium plus yttrium 37 Essential Medicines List 37 Post hoc 36 surface glycoprotein 36 fluorescence polarization 36 Lipid lowering 36 JM Dutton adds 36 Mechanistic studies 36 Subgroup analyzes 36 Dickersin 36 CCN2 36 Johan Löf 36 CSL Behring therapies 36 serotonin 2C receptor 36 human IgG2 monoclonal 36 voyage charters 36 SNP rs# [002] 36 IntroductionThe 36 hCG β 36 Cytogen periodic filings 36 OvPlex ™ 36 circulating endothelial cells 36 Nabriva 36 mucosal immune responses 36 Ph3 36 ERa 35 Randomised controlled trials 35 HGD 35 Mr. Palagiano 35 Looking Statements Statements 35 transgenic hens 35 Bcl 2 35 axon outgrowth 35 JPI JJB 35 gene rearrangements 35 stromal derived 35 MAGE A3 antigen 35 Cheniere Partners 35 cyclin D1 35 Intergroup Exemestane Study 35 GI mucosa resulting 35 postprandial hyperglycemia 35 recombinant therapeutic 35 VIDAZA azacitidine 35 Cytogen dependence 35 Nick Leschly 34 monoclonal antibodies aptamers 34 Garnet Biotherapeutics 34 Septin 9 biomarker 34 insecticidal proteins 34 tropism assay 34 Atrush 34 stepwise fashion 34 Beyondie 34 Nrf2 gene 34 HER2/neu gene 34 ConclusionThis 34 Novartis AG nonsteroidal anti 34 epithelial markers 34 MIF gene 34 Handcamp property 34 mGluR5 inhibition 34 EPS accretion 34 Tabular amounts 33 educational purposes.Petroleumworld 33 unmeasured confounding 33 PolyNovo 33 asignificant 33 osteogenic differentiation 33 whatsoever warranties 33 PortAl Iraq 33 ErbB2 33 unknown risks anduncertainties 33 genotype phenotype 33 gastric stasis 33 Previous epidemiological studies 33 rhabdoid tumors 32 Dr. Gapontsev 32 Logistic regression analyzes 32 rotavirus vaccine Wyeth RotaShield 32 L1 CAM 32 prospectively 32 pre malignant lesions 32 putative biomarkers 32 Haib Project 32 subsidiary ChipMOS TECHNOLOGIES 32 Trial ALLHAT 32 Epidemiologic studies 32 Mr. Feldenkreis 32 Goodbody Stockbrokers adds 32 #.These statements 32 misfolded SOD1 32 Prospectively 32 Consolidated Balance Sheets Amounts 32 Bacille Calmette Guérin BCG 32 Mr. Longever 31 epigenetic biomarkers 31 Command Antivirus 31 hereby expressly disclaimed 31 Clinical trials 31 activates guanylate cyclase C 31 Inaddition 30 -monoammonium phosphate 30 elements lanthanum 30 implied therein 30 Dr. Urnovitz 30 Carlo Alberto Defanti 30 CONTRACTUAL OBLIGATIONS 30 Webelieve 30 Cognitive impairment 29 transgenic rabbits 29 AramcoAramco 29 Disclaimer Views 29 LV systolic function 29 abusive slanderous 29 Ms. Brolick 29 http:/www.thesop.org/article.php?id=# Any opiniruble denominated Micex 29 Jihad Unspun 29 Bobbie Palfrey 29 TSX VENTURE EEL FRANKFURT 28 LOSS AND DEFICIT 28 Biophan periodic filings 28 al Zurufi 28 Epidemiological studies 28 blackened frostbitten toes 28 Panamax Bulk Carrier 28 privacy Gayan 28 CHINA BIOTICS INC. AND 28 Firefighter Elias Jacquez 28 Retained Earnings unaudited 28 BCCs 28 Observational studies 27 EEAICP 27 Vudhibhandhu 27 LOSS Unaudited 27 PSMA protein highly 27 MRO Supplies 27 Cautionary Statements 27 Sayel al Khalayleh 27 concerning Timminco 27 FDA El Hinnawy 27 RGE takes 27 Parliament speaker Hajim 27 MUICP 27 significant 27 awkwardly backpedaled 26 INTERIM CONSOLIDATED BALANCE SHEET 26 INC. Consolidated Statement 26 Jines missing 26 INTERIM CONSOLIDATED STATEMENT OF 26 http:/www.thesop.org/article.php?id=# Any opinbastardization 26 briefly summarizes 26 Massooda Jalal 26 Vast Exploration 26 Hanna Barbera animations 26 Gen. Sher 26 filings Infinium Labs 26 deep regretfulness 26 interest Angola Sonogal 25 Interim Consolidated Statements 25 InCard filings 25 Mexican Pesos Ps 25 Cerberus ABP 25 http:/www.thesop.org/article.php?id=# Any opiBurbee 25 withdrawn Vioxx painkiller 25 Safiadeen 25 Professional Magazine NationalMortgageProfessionalJoseph Villalta 25 mathematician Marin Mersenne 25 Deficit Unaudited 25 ally Margherita Boniver 25 anal glands 24 Roseby Copper Project 24 FactSet Mergerstat LLC 24 Kadimiyah hospital 24 Bleichwehl 24 spokesman Stan Steinreich 24 Printelligence TM 24 custody Jehl 24 Qualitatively 24 Kut morgue 24 beads toting parasols 24 Secondarily 24 factor receptor PDGFR 24 Allawi bloc 24 spokesman Hiwa Othman 24 ethnic Uzbek warlord 24 NPS periodic filings 24 nyse LDK 23 -BY LEE MAREE 23 http:/www.realpennies.com/start.html Any opinionsBRSU 23 premeditation Delucchi 23 ERHC Energy 23 Dongguan AIVtech 23 Operationally 23 Jinane Adra 23 conservator Streisand 23 SAIRI 23 KUFPEC 23 spiritual closeness 23 Inc. NASDAQ BPOP 22 Bcl xL protein 22 Designerware product 22 spokesman Steve Swasey 22 United Coalbed Methane 22 Salahaddin province 22 Mansuriyah 22 Consistent 22 Arabiya television 22 moored semisubmersible rigs 22 al Sumeidi 22 legislator Baha 22 wahpetondailynews.com s reader 22 Zarechnoye 22 Abdul Mehdi 22 mitigant 22 Ayatollah Mohammed 22 hardline Shiite cleric 22 Kealakehe farther north 22 al Sadr reappearance 22 HOCKENHEIM Germany Fernando Alonso 22 Occam Networks stockholders 21 arrestin 21 furthermore 21 CSIA Apex Awards 21 director Catherine Bentwood 21 Mazaya Holding 21 Daniel Vigee head 21 Dera Sachh Khand sect 21 Al Sistani 21 Hilal Cement 21 Principally 21 Dirioz 21 Al Rafidayn 21 Tomas Neeley 21 Sadreddin al 21 chief Siegfried Sievert 21 mutant DISC1 21 Accordingly 21 anymore JSB Blatter 21 saukvalley.com s story 21 Boroujerd 21 Al Yarmuk 20 ELEKS 20 MBAI 20 Al Baghdadiya 20 al Mehri 20 TotalTotal 20 Subsequent 20 RenewAmerica columnists 20 Student Operated Press 20 ruined hillsides 20 SFDugout.com 20 Awilco 20 Significantly 20 utter revulsion 20 Interior Minister Abdolvahed 20 Lanjigarh Orissa 20 accountants PricewaterhouseCoopers LLP 20 Empirical evidence 20 ideological affinity 20 Chief Executive Hans Vestberg 20 Esbaitah 20 Qayara 20 eminence al Sistani 20 Dr. Patricio Guijon 19 Ecopetrol ECOPETROL.BO 19 Chaldean Catholic Archbishop Paulos 19 Aman Sulaiman 19 Ali Sistani 19 Gov. Mario Cossio 19 Perrachon